Alaunos Therapeutics, Inc. (NASDAQ: TCRT) is a clinical‐stage biotechnology company focused on developing in vivo cell reprogramming therapies for neurodegenerative diseases and chronic pain. By harnessing proprietary gene delivery platforms, Alaunos aims to convert resident support cells in the central nervous system into functional neurons or inhibitory interneurons, offering potential long-lasting treatments for conditions with high unmet medical need.
The company’s lead program targets amyotrophic lateral sclerosis (ALS) through adeno-associated virus (AAV) vectors that deliver neural lineage factors to reprogram astrocytes into motor neurons, with the goal of restoring neuromuscular function. A second preclinical initiative seeks to alleviate neuropathic pain by converting spinal cord glial cells into GABAergic interneurons, potentially providing durable pain relief without the drawbacks of systemic analgesics.
Founded in 2017 and headquartered in Cambridge, Massachusetts, Alaunos leverages a multidisciplinary research footprint spanning North America and Europe. The organization maintains strategic collaborations with leading academic institutions and contract research partners to advance its platform technology, optimize vector design and manufacture clinical-grade materials in accordance with regulatory standards.
Under the leadership of President and Chief Executive Officer Dr. Ryan Berry, a molecular neuroscientist with extensive experience in gene therapy development, Alaunos has assembled a management team with expertise in translational neuroscience, clinical development and regulatory affairs. The company remains focused on progressing its pipeline through IND-enabling studies and initial human trials, with the aim of delivering transformative therapies to patients suffering from ALS and neuropathic pain.
AI Generated. May Contain Errors.
